| 1 |
9,540,623 |
 |
Method for increasing the efficiency of double-strand-break induced mutagenesis |
| 2 |
9,540,609 |
|
Lactobacillus rhamnosus food grade bacteria |
| 3 |
9,512,476 |
|
Method of DNA sequencing by hybridisation |
| 4 |
9,511,136 |
|
Immunogenic compounds comprising HIV GP41 peptide coupled to CRM197 carrier protein |
| 5 |
9,499,799 |
|
Cells and methodology to generate non-segmented negative-strand RNA viruses |
| 6 |
9,493,829 |
|
Method of DNA sequencing by polymerisation |
| 7 |
9,492,524 |
|
Plague vaccine |
| 8 |
9,476,086 |
|
Bacteriophage with activity against pathogenic strains of Salmonella |
| 9 |
9,475,870 |
|
Single domain binding molecule |
| 10 |
9,442,114 |
|
Isolated and purified strains of Chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof |
| 11 |
9,410,139 |
|
Recombinant adenylate cyclase toxin of bordetella induces T cell responses against tumoral antigens |
| 12 |
9,404,142 |
|
Screening methods for identifying Plasmodium proteases inhibitors |
| 13 |
9,403,880 |
|
Identification of a human gyrovirus and applications |
| 14 |
9,403,871 |
|
Methods for treating pain by administering peptides derived from human basic proline-rich lacrimal protein |
| 15 |
9,392,792 |
|
Topical combination of fipronil, permethrin and pyriproxyfen |
| 16 |
9,387,243 |
|
Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof |
| 17 |
9,382,338 |
|
Polysaccharide and derivatives thereof, showing affinity to ficolin-3, method of preparation and use |
| 18 |
9,370,564 |
|
Vectors for molecule delivery to CD11b expressing cells |
| 19 |
9,365,864 |
|
Meganuclease recombination system |
| 20 |
9,359,323 |
|
Compound |
| 21 |
9,347,088 |
|
Molecular signature of liver tumor grade and use to evaluate prognosis and therapeutic regimen |
| 22 |
9,328,163 |
|
Post-translationally modified neurotrophin antibodies |
| 23 |
9,328,146 |
|
Lentiviral gene transfer vectors and their medicinal applications |
| 24 |
9,315,552 |
|
Recombinant cytotoxin as well as a method of producing it |
| 25 |
9,290,748 |
|
Use of endonucleases for inserting transgenes into safe harbor loci |
| 26 |
9,273,276 |
|
Devices and methods for pharmacokinetic-based cell culture system |
| 27 |
9,273,094 |
|
Opiorphin peptide derivatives as potent inhibitors of enkephalin-degrading ectopeptidases |
| 28 |
9,243,221 |
|
Compositions and methods of functionally enhanced in vitro cell culture system |
| 29 |
9,238,824 |
|
Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA |
| 30 |
9,222,143 |
|
Mutant CyaA polypeptides and polypeptide derivatives suitable for the delivery of immunogenic molecules into a cell |
| 31 |
9,201,076 |
|
Upregulation of rack-1 in melanoma and its use as a marker |
| 32 |
9,173,933 |
|
Recombinant modified vaccinia virus Ankara influenza vaccine |
| 33 |
9,164,107 |
|
HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders |
| 34 |
9,164,103 |
|
Monitoring and inhibiting human immunodeficiency virus infection by modulating HMGB1 dependent triggering of HIV-1 replication and persistence |
| 35 |
9,163,237 |
|
Replication deficient recombinant viruses expressing antigens regulated by transcriptional control elements comprising multiple elements |
| 36 |
9,149,515 |
|
Interferon-alpha-producing bone marrow dendritic cells |
| 37 |
9,109,234 |
|
Lentiviral vector based immunological compounds against malaria |
| 38 |
9,109,233 |
|
Recombinant poxvirus expressing homologous genes inserted |
| 39 |
9,109,219 |
|
MGMT-based method for obtaining high yields of recombinant protein expression |
| 40 |
9,109,201 |
|
Purification of vaccinia viruses using hydrophobic interaction chromatography |
| 41 |
9,096,868 |
|
Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use |
| 42 |
9,095,537 |
|
Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response |
| 43 |
9,074,186 |
|
Production of red blood cells and platelets from stem cells |
| 44 |
9,074,182 |
|
Differentiated pluripotent stem cell progeny depleted of extraneous phenotypes |
| 45 |
9,029,145 |
|
Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof |
| 46 |
9,023,645 |
|
Isolated in vitro cell population comprising primate pluripotent stem cells containing a nucleic acid construct and differentiated progeny of the pluripotent stem cells |
| 47 |
9,012,214 |
|
Recombinant measles viruses expressing epitopes of antigens of RNA viruses–use for the preparation of vaccine compositions |
| 48 |
9,005,961 |
|
Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions |
| 49 |
9,547,006 |
|
Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus |
| 50 |
9,546,380 |
|
MGMT-based method for obtaining high yields of recombinant protein expression |
